Pregabalin Capsule
Product Images NDC 71205-872

Product Visual Gallery

This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71205-872). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Pregabalin 01)

Chemical structure diagram of Pregabalin, the active ingredient shown as a molecular formula with labeled functional groups including an amino group (NH2) and a carboxyl group (CO2H).*

FDA Label Image

Figure 1 (Pregabalin 02)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at 200 mg, 100 mg, and 25 mg taken three times a day, compared to placebo. The x-axis represents percent improvement in pain from baseline, and the y-axis shows the percent of patients improved. Different line styles represent each dosage and placebo.*

FDA Label Image

Figure 2 (Pregabalin 03)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline. It compares two groups: Pregabalin 100 mg three times a day and placebo. The Y-axis represents the percent of patients improved, while the X-axis shows percent improvement in pain from baseline, from 0 to 100%.*

FDA Label Image

Figure 3 (Pregabalin 04)

A line graph showing the percent of patients improved plotted against the percent improvement in pain from baseline. The graph compares Pregabalin dosages of 75 mg, 150 mg, and 300 mg taken two times a day, along with a placebo group, illustrating differences in patient improvement across the treatment groups.*

FDA Label Image

Figure 4 (Pregabalin 05)

A line graph showing percent of patients improved relative to percent improvement in pain from baseline. It compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, with the y-axis representing the percent of patients improved and the x-axis representing percent improvement in pain from baseline.*

FDA Label Image

Figure 5 (Pregabalin 06)

A line graph depicting the percent of patients improved on the vertical axis against the percent improvement in pain on the horizontal axis. The graph compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and Placebo, showing the response distribution across different pain improvement levels.*

FDA Label Image

Figure 6 (Pregabalin 07)

A bar graph showing responder rates (%) comparing different dosages of Pregabalin versus placebo in two clinical studies labeled Study E1 and Study E3. Study E1 presents responder rates for placebo, 50 mg/day, 150 mg/day, 300 mg/day, and 600 mg/day dosages, while Study E3 compares placebo, 300 mg/day BID, and 600 mg/day TID. The y-axis represents responder rate in percentage, and the x-axis lists the treatment groups and dosage regimens.*

FDA Label Image

Figure 7 (Pregabalin 08)

A line chart depicting the median percentage change from baseline in seizure reduction versus dose (mg/day) for Pregabalin across three studies (E1, E2, E3) with BID and TID dosing schedules. Data points indicate seizure reduction increases with dose, and significant p-values are noted for comparisons to placebo.*

FDA Label Image

Figure 9 (Pregabalin 09)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at daily doses of 300 mg, 450 mg, and 600 mg compared to placebo. The x-axis represents percent improvement in pain from baseline (0 to 100%), and the y-axis shows the percent of patients improved. Data lines for each dosage and placebo trend downward as percent improvement increases, with vertical reference lines at approximately 30% and 50% improvement.*

FDA Label Image

Figure 10 (Pregabalin 10)

A line graph comparing the estimated percentage of subjects without LTR over 180 days between Pregabalin and placebo groups. The y-axis represents the percentage of subjects without LTR, ranging from 0% to 100%, and the x-axis represents days, from 0 to 180. The Pregabalin group shows a higher percentage of subjects without LTR across the period compared to the placebo group.*

FDA Label Image

Figure 11 (Pregabalin 11)

A line graph showing the percent of subjects improved over a range of 0 to 100 percent improvement from baseline to Week 12 based on BOCF (Baseline Observation Carried Forward) analysis. Two lines compare Pregabalin and placebo, with Pregabalin showing higher improvement percentages across the range.*

FDA Label Image

Figure 12 (Pregabalin 12)

A line graph showing the percent of subjects improved on the y-axis versus percent improved from baseline to week 16 BOCF on the x-axis. Two lines represent Pregabalin and placebo groups, illustrating comparative improvement over time.*

FDA Label Image

71205-869-30 (Pregabalin 13)

Label for Pregabalin 25 mg capsules by Proficient Rx LP. The package contains 30 capsules, each with 25 mg of pregabalin. The capsules are white to off-white powder filled in size 4 hard gelatin capsules with white opaque colored cap and white opaque colored body imprinted with "SG" on cap and "350" on body with black ink. The product is prescription only (C-V), manufactured by SciGen Pharmaceuticals, Inc.*

FDA Label Image

71205-870-30 (Pregabalin 14)

Label for Pregabalin 50 mg capsules by Proficient Rx LP, containing 60 capsules. The label states each capsule contains 50 mg pregabalin and includes directions to dispense the accompanying medication guide. Capsules are described as white to off white powder filled gelatin capsules with specific markings 'SG' and '351' in black ink. Storage instructions note 25°C (77°F).*

FDA Label Image

71205-871-30 (Pregabalin 15)

Pregabalin 75 mg capsules label from Proficient Rx LP. The label indicates a quantity of 30 capsules per package, prescription use only with a Schedule C-V classification. It specifies each capsule contains 75 mg of pregabalin and includes storage instructions at 25°C (77°F). Manufacturer is SciGen Pharmaceuticals, Inc., Hauppauge, NY.*

FDA Label Image

71205-872-30 (Pregabalin 16)

Pregabalin 100 mg capsules packaging label by Proficient Rx LP. The label includes the proprietary and generic name Pregabalin, strength 100 mg, and quantity #100. It states capsules as the dosage form and oral route. The label instructs to dispense the accompanying Medication Guide and lists the product ID and manufacturer information from ScieGen Pharmaceuticals. The label also includes regulatory markings like RX Only and controlled substance schedule C-V.*

FDA Label Image

71205-873-30 (Pregabalin 17)

Pregabalin 150 mg capsules packaging label from Proficient Rx LP. The label indicates a 30-capsule supply with each capsule containing 150 mg pregabalin. Capsules are described as white powder-filled, size 2 hard gelatin with distinct white opaque colored caps marked with 'SG' and '354'. The label includes storage instructions and manufacturer details from SieGen Pharmaceuticals, Inc.*

FDA Label Image

71205-874-30 (Pregabalin 18)

Pregabalin 200 mg capsules packaging label from Proficient Rx LP. The label indicates 30 capsules per container with each capsule containing 200 mg of pregabalin. It includes dispensing information, storage instructions, and manufacturer details by SciGen Pharmaceuticals, Inc., Hauppauge, NY. The label also shows the NDC 71205-874-30 and controlled substance schedule C-V.*

FDA Label Image

71205-875-30 (Pregabalin 19)

Label for Pregabalin 225 mg capsules by Proficient Rx LP. The bottle contains 30 capsules, each with 225 mg pregabalin. Capsules are described as white to off-white powder filled in size 1 hard gelatin capsules with light orange caps and white opaque bodies imprinted with 'SG' on the cap and '356' on the body in black ink. The label includes storage instructions and a caution to keep medication out of reach of children.*

FDA Label Image

71205-876-30 (Pregabalin 20)

Label for Pregabalin 300 mg oral capsules, #60 count, manufactured by Proficient Rx LP and SciGen Pharmaceuticals, Inc. The label includes dispensing instructions, medication identification details, and storage conditions. The capsules are described as white to off-white powder in size '0' hard gelatin capsules with orange opaque colored caps and white opaque bodies, marked with 'SG' and '357' in black ink.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.